| Chronic Kidney Diseases
Nutropin AQ vs Furoscix
Side-by-side clinical, coverage, and cost comparison for chronic kidney diseases.Deep comparison between: Nutropin Aq Nuspin 10 vs Furoscix with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFuroscix has a higher rate of injection site reactions vs Nutropin Aq Nuspin 10 based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Furoscix but not Nutropin Aq Nuspin 10, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nutropin Aq Nuspin 10
Furoscix
At A Glance
SC injection
Daily
Recombinant human growth hormone
SC injection
Loop diuretic
Indications
- Somatotropin deficiency
- Turner Syndrome
- Chronic Kidney Diseases
- Edema
- Chronic heart failure
- Chronic Kidney Diseases
- Nephrotic Syndrome
Dosing
Somatotropin deficiency (pediatric) Up to 0.3 mg/kg/week divided into daily SC injections; pubertal patients may use up to 0.7 mg/kg/week divided daily.
Somatotropin deficiency (adult) Weight-based: starting dose up to 0.006 mg/kg/day SC, max 0.025 mg/kg/day (age <=35 years) or 0.0125 mg/kg/day (age >35 years); or non-weight-based: starting dose approximately 0.2 mg/day SC with gradual titration every 1-2 months.
Chronic Kidney Diseases Up to 0.35 mg/kg/week divided into daily SC injections; therapy may continue until renal transplantation.
Turner Syndrome Up to 0.375 mg/kg/week divided into equal doses 3 to 7 times per week by SC injection.
Edema, Chronic heart failure, Chronic Kidney Diseases, Nephrotic Syndrome 30 mg subcutaneously over the first hour followed by 12.5 mg per hour for the subsequent 4 hours (total 80 mg) via On-body Infusor applied to the abdomen; not for chronic use, replace with oral diuretics as soon as practical.
Contraindications
- Acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Prader-Willi syndrome in children with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
- Active malignancy
- Known hypersensitivity to somatropin or any excipient
- Active proliferative or severe non-proliferative diabetic retinopathy
- Closed epiphysis (for growth promotion in pediatric patients)
- Anuria
- History of hypersensitivity to furosemide, any component of the FUROSCIX formulation, or medical adhesives
Adverse Reactions
Most common Edema or peripheral edema (adults with GHD), arthralgias (adults with GHD), otitis media and ear disorders (Turner syndrome), injection site discomfort (pediatric GHD)
Serious Intracranial hypertension, glucose intolerance, slipped capital femoral epiphysis, scoliosis progression, leukemia, pancreatitis, severe hypersensitivity reactions, hypothyroidism, hypoadrenalism, lipoatrophy
Postmarketing Anaphylaxis, angioedema, leukemia, gynecomastia (children), pancreatitis, slipped capital femoral epiphysis, osteonecrosis
Serious fluid, electrolyte, and metabolic abnormalities, ototoxicity, anaphylactic or anaphylactoid reactions, aplastic anemia, toxic epidermal necrolysis, Stevens-Johnson syndrome, interstitial nephritis, necrotizing angiitis
Other reported pancreatitis, jaundice, nausea, vomiting, tinnitus, hearing loss, vertigo, dizziness, headache, thrombocytopenia, agranulocytosis, leukopenia, rash, erythema multiforme, orthostatic hypotension, injection site erythema and pain, muscle spasm, restlessness
Pharmacology
Somatropin is a recombinant human growth hormone that binds to dimeric GH receptors on target cell membranes, triggering intracellular signal transduction; pharmacodynamic effects include skeletal growth and protein synthesis mediated via IGF-1, as well as direct effects such as lipolysis.
Furosemide is a loop diuretic that primarily inhibits sodium and chloride reabsorption in the proximal and distal tubules and the loop of Henle, producing high-degree diuresis independent of carbonic anhydrase inhibition or aldosterone.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nutropin Aq Nuspin 10
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Furoscix
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Nutropin Aq Nuspin 10
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Furoscix
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Nutropin Aq Nuspin 10
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Furoscix
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Nutropin Aq Nuspin 10.
No savings programs available for Furoscix.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Nutropin Aq Nuspin 10View full Nutropin Aq Nuspin 10 profile
FuroscixView full Furoscix profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.